Consultancies and advisers
An engagement on a European medicine turns on a handful of facts: when protection ends in each market, who holds the licences, what the published price is and where the generics are. MPA has supplied those facts to consultancies and advisers for decades, with the register references to stand behind them in front of a client.
The questions you face
For a due diligence or a valuation, what is the real exclusivity position of the target products in each European market, behind the headline expiry date?
For a market entry study, which products open up in the next few years, who already holds licences, and what are the published prices across the markets in scope?
How quickly can a defensible answer be assembled under an engagement deadline, without a team reading thirty-two registers?
When two published sources disagree on a date or a holder, which one is right, and how is that shown to the client?
How MPA helps
The official data, kept current, with the experience to read it. We have done this since 1973.
One source for 32 countries
Patents, SPCs, paediatric extensions, first authorisation dates, UK and European licences, parallel import licences and published prices, maintained from the official registers and searchable together.
Built for the deadline
Search by molecule, product, holder or country, compare markets side by side and export what the engagement needs. Subscriptions run for twelve months and cover the whole team.
Experience on call
When a record needs interpreting or a conclusion needs checking, ask us. We have followed these markets since 1973 and have supported consultancy engagements for most of that time.
What to read first
All resources- ExplainersOne product, five clocksPatent expiry, SPC expiry, paediatric extension, data exclusivity and market protection are five separate clocks on one product. They start from different events, run under different laws, and the last one to stop sets the real loss-of-exclusivity date. A one-page map, with a checklist.
- ExplainersWhy published patent-expiry lists disagree, and how to check a date yourselfSearch for any blockbuster's European patent expiry and you will find three different years. The lists are not all wrong; they are measuring different things. The six reasons they diverge, and a short procedure for getting the date that applies to your product and country.
- ExplainersPatent cover, data exclusivity and market protectionPatents are only one of the barriers between a generic and the market. Regulatory data protection runs on its own clock from the first EU authorisation and can block generics when no patent does. What the 8+2+1 rule means, how the UK and EU now differ, and what the 2026 reform changes.
- ExplainersThe generic development timeline in EuropeA generic cannot be filed until year eight of the reference product's data protection and cannot be sold until year ten, so development is timed backwards from a date. What each step takes for an oral solid, where the Bolar exemption covers it, what the application costs in time, why complex generics and biosimilars start years earlier, and what the programme means for the launch date everyone else is watching.
- PricesHow medicine list prices are published across EuropeThere is no European price list. Each country publishes its own, in its own format, showing a different point on the price ladder, on a different schedule, and some publish nothing free at all. A country-by-country map of the official sources, written for people comparing prices across borders.
- GlossaryCountry codes and the registers behind themThe two-letter codes on patent documents, licence numbers and price lists, for every country MPA covers: EU or not, which office grants patents and SPCs, which agency licenses medicines, which currency the prices are in, and the special codes (EP, WO, EU, XI) that are not countries at all.
See MPA Search in action
A free online demonstration with our team, with time for your questions.